Comparative Efficacy of Analgesics for Pain Relief in Patients with Symptomatic Irreversible Pulpitis Prior to Emergency Endodontic Treatment: A Randomized Controlled Trial.
Ali Eslambol Nassaj, Amir Hossein Nekouei, Rahim Fereidooni, Homa Kamyabi, Abbas Pardakhty, Arash Shahravan
{"title":"Comparative Efficacy of Analgesics for Pain Relief in Patients with Symptomatic Irreversible Pulpitis Prior to Emergency Endodontic Treatment: A Randomized Controlled Trial.","authors":"Ali Eslambol Nassaj, Amir Hossein Nekouei, Rahim Fereidooni, Homa Kamyabi, Abbas Pardakhty, Arash Shahravan","doi":"10.22037/iej.v18i4.35469","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the efficacy of ibuprofen, Novafen, mefenamic acid (MA), and celecoxib for pain relief in patients with symptomatic irreversible pulpitis prior to emergency endodontic treatment.</p><p><strong>Materials and methods: </strong>This clinical trial was conducted on 120 patients with moderate to severe pain due to symptomatic irreversible pulpitis seeking emergency endodontic treatment. The patients were randomly divided into 4 groups to receive Novafen, MA, Celecoxib, and ibuprofen. The pain score of patients was measured before and 1 hour after analgesic intake using a visual analog scale (VAS). The success of analgesic treatment was analyzed by the binary logistic regression model.</p><p><strong>Results: </strong>A total of 117 patients including 76 females and 41 males with a mean age of 30.29 years completed the study and were statistically analyzed. Ibuprofen had the highest analgesic efficacy followed by Novafen, and caused a significantly greater reduction in pain score compared with MA and celecoxib [OR (Ibuprofen vs MA)=1.28, OR (Ibuprofen vs Celecoxib)=3.74, OR (Novafen vs MA)=2.94, OR (Novafen vs Celecoxib)=2.94, <i>P</i><0.05]. Ibuprofen and Novafen had no significant difference in analgesic efficacy (<i>P</i>>0.05). Baseline pain score was a predictive factor for the success of analgesics (<i>P</i><0.05). The success of analgesic treatment decreased by 0.68 times with each unit increase in pain score (<i>P</i><0.05). Gender and age of patients had no significant effect on success of analgesics (<i>P</i>>0.05).</p><p><strong>Conclusion: </strong>Both ibuprofen and Novafen can serve as the analgesics of choice for pain relief in patients with symptomatic irreversible pulpitis with moderate to severe pain when emergency endodontic treatment cannot be immediately performed.</p>","PeriodicalId":14534,"journal":{"name":"Iranian Endodontic Journal","volume":"18 4","pages":"194-201"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0e/83/IEJ-18-194.PMC10565996.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Endodontic Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22037/iej.v18i4.35469","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study aimed to compare the efficacy of ibuprofen, Novafen, mefenamic acid (MA), and celecoxib for pain relief in patients with symptomatic irreversible pulpitis prior to emergency endodontic treatment.
Materials and methods: This clinical trial was conducted on 120 patients with moderate to severe pain due to symptomatic irreversible pulpitis seeking emergency endodontic treatment. The patients were randomly divided into 4 groups to receive Novafen, MA, Celecoxib, and ibuprofen. The pain score of patients was measured before and 1 hour after analgesic intake using a visual analog scale (VAS). The success of analgesic treatment was analyzed by the binary logistic regression model.
Results: A total of 117 patients including 76 females and 41 males with a mean age of 30.29 years completed the study and were statistically analyzed. Ibuprofen had the highest analgesic efficacy followed by Novafen, and caused a significantly greater reduction in pain score compared with MA and celecoxib [OR (Ibuprofen vs MA)=1.28, OR (Ibuprofen vs Celecoxib)=3.74, OR (Novafen vs MA)=2.94, OR (Novafen vs Celecoxib)=2.94, P<0.05]. Ibuprofen and Novafen had no significant difference in analgesic efficacy (P>0.05). Baseline pain score was a predictive factor for the success of analgesics (P<0.05). The success of analgesic treatment decreased by 0.68 times with each unit increase in pain score (P<0.05). Gender and age of patients had no significant effect on success of analgesics (P>0.05).
Conclusion: Both ibuprofen and Novafen can serve as the analgesics of choice for pain relief in patients with symptomatic irreversible pulpitis with moderate to severe pain when emergency endodontic treatment cannot be immediately performed.
引言:本研究旨在比较布洛芬、诺瓦芬、甲非那米酸(MA)和塞来昔布在紧急牙髓治疗前缓解症状性不可逆牙髓炎患者疼痛的疗效。材料和方法:本临床试验对120例因症状性不可逆牙髓炎引起的中重度疼痛寻求紧急牙髓治疗的患者进行。患者被随机分为4组,分别接受诺瓦芬、MA、塞来昔布和布洛芬治疗。使用视觉模拟量表(VAS)在服用止痛药之前和之后1小时测量患者的疼痛评分。采用二元逻辑回归模型分析镇痛治疗的成功率。结果:共有117名患者完成了研究并进行了统计分析,其中包括76名女性和41名男性,平均年龄30.29岁。布洛芬具有最高的镇痛效果,其次是Novafen,与MA和塞来昔布相比,导致疼痛评分显著降低[OR(布洛芬vs MA)=1.28,OR(布洛芬vs塞来昔布)=3.74,OR(Novafen vs MA)=2.94,OR结论:布洛芬和诺伐芬都可以作为缓解症状性不可逆牙髓炎患者疼痛的首选镇痛药,当不能立即进行紧急牙髓治疗时,伴有中度至重度疼痛。
期刊介绍:
The Iranian Endodontic Journal (IEJ) is an international peer-reviewed biomedical publication, the aim of which is to provide a scientific medium of communication for researchers throughout the globe. IEJ aims to publish the highest quality articles, both clinical and scientific, on all aspects of Endodontics. The journal is an official Journal of the Iranian Center for Endodontic Research (ICER) and the Iranian Association of Endodontists (IAE). The Journal welcomes articles related to the scientific or applied aspects of endodontics e.g. original researches, systematic reviews, meta-analyses, review articles, clinical trials, case series/reports, hypotheses, letters to the editor, etc. From the beginning (i.e. since 2006), the IEJ was the first open access endodontic journal in the world, which gave readers free and instant access to published articles and enabling them faster discovery of the latest endodontic research.